title: Analysis of Major Histocompatibility Complex-Bound HIV Peptides Identified from Various Cell Types Reveals Common Nested Peptides and Novel T Cell Responses.
abstract: Despite the critical role of epitope presentation for immune recognition, we still lack a comprehensive definition of HIV peptides presented by HIV-infected cells. Here we identified 107 major histocompatibility complex (MHC)-bound HIV peptides directly from the surface of live HIV-transfected 293T cells, HIV-infected B cells, and primary CD4 T cells expressing a variety of HLAs. The majority of peptides were 8 to 12 amino acids (aa) long and mostly derived from Gag and Pol. The analysis of the total MHC-peptidome and of HLA-A02-bound peptides identified new noncanonical HIV peptides of up to 16 aa that could not be predicted by HLA anchor scanning and revealed an heterogeneous surface peptidome. Nested sets of surface HIV peptides included optimal and extended HIV epitopes and peptides partly overlapping or distinct from known epitopes, revealing new immune responses in HIV-infected persons. Surprisingly, in all three cell types, a majority of Gag peptides derived from p15 rather than from the most immunogenic p24. The cytosolic degradation of peptide precursors in corresponding cells confirmed the generation of identified surface-nested peptides. Cytosolic degradation revealed peptides commonly produced in all cell types and displayed by various HLAs, peptides commonly produced in all cell types and selectively displayed by specific HLAs, and peptides produced in only one cell type. Importantly, we identified areas of proteins leading to common presentations of noncanonical peptides by several cell types with distinct HLAs. These peptides may benefit the design of immunogens, focusing T cell responses on relevant markers of HIV infection in the context of HLA diversity.
  
  
  
  The recognition of HIV-infected cells by immune T cells relies on the presentation of HIV-derived peptides by diverse HLA molecules at the surface of cells. The landscape of HIV peptides displayed by HIV-infected cells is not well defined. Considering the diversity of HLA molecules in the human population, it is critical for vaccine design to identify HIV peptides that may be displayed despite the HLA diversity. We identified 107 HIV peptides directly from the surface of three cell types infected with HIV. They corresponded to nested sets of HIV peptides of canonical and novel noncanonical lengths not predictable by the presence of HLA anchors. Importantly, we identified areas of HIV proteins leading to presentation of noncanonical peptides by several cell types with distinct HLAs. Including such peptides in vaccine immunogen may help to focus immune responses on common markers of HIV infection in the context of HLA diversity.
authors.affiliation: Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Harvard Medical School, Cambridge, Massachusetts, USA.
authors.forename: Marijana
authors.initials: M
authors.lastname: Rucevic
authors.affiliation: Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Harvard Medical School, Cambridge, Massachusetts, USA.
authors.forename: Georgio
authors.initials: G
authors.lastname: Kourjian
authors.affiliation: Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Harvard Medical School, Cambridge, Massachusetts, USA.
authors.forename: Julie
authors.initials: J
authors.lastname: Boucau
authors.affiliation: Immunotherapy and Prevention, German Cancer Research Center (DKFZ), Heidelberg, Germany, and Molecular Vaccine Design, German Center for Infection Research (DZIF), Heidelberg, Germany.
authors.forename: Renata
authors.initials: R
authors.lastname: Blatnik
authors.affiliation: Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Harvard Medical School, Cambridge, Massachusetts, USA.
authors.forename: Wilfredo
authors.initials: W
authors.lastname: Garcia Bertran
authors.affiliation: Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Harvard Medical School, Cambridge, Massachusetts, USA.
authors.forename: Matthew J
authors.initials: MJ
authors.lastname: Berberich
authors.affiliation: Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Harvard Medical School, Cambridge, Massachusetts, USA Howard Hughes Medical Institute (HHMI), Chevy Chase, Maryland, USA.
authors.forename: Bruce D
authors.initials: BD
authors.lastname: Walker
authors.affiliation: Immunotherapy and Prevention, German Cancer Research Center (DKFZ), Heidelberg, Germany, and Molecular Vaccine Design, German Center for Infection Research (DZIF), Heidelberg, Germany.
authors.forename: Angelika B
authors.initials: AB
authors.lastname: Riemer
authors.affiliation: Ragon Institute of MGH, MIT and Harvard, Massachusetts General Hospital, Harvard Medical School, Cambridge, Massachusetts, USA sylvie_legall@hms.harvard.edu.
authors.forename: Sylvie
authors.initials: S
authors.lastname: Le Gall
mesh_terms: D017951:Antigen Presentation; D001402:B-Lymphocytes / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D002478:Cells, Cultured; D004847:Epithelial Cells / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D006678:HIV / Q000276:immunology*; D015488:HIV Antigens / Q000032:analysis*; D006649:Histocompatibility Antigens / Q000737:chemistry*; D006801:Humans; D010455:Peptides / Q000032:analysis*
chemical_list: D018984:Epitopes, T-Lymphocyte; D015488:HIV Antigens; D006649:Histocompatibility Antigens; D010455:Peptides